Truist and Mizuho Back MNKD on Tyvaso Progress
Watch: Monitor May 29 Afrezza pediatric approval; a green light could broaden market base and stabilize MNKD's downtrend.
Full analysis
Truist Securities reaffirmed its Buy rating with a $7 target after United Therapeutics' Phase III trial for Tyvaso showed a 111.8 mL lung capacity gain in 598 IPF patients. MannKind seeks $1 billion in sales from Tyvaso within five years, bolstered by its planned acquisition of scPharmaceuticals to boost cardiometabolic revenue. Mizuho also maintains Outperform on MNKD, reflecting sustained analyst support.
Positive trial data and analyst endorsements signal strong growth potential in the IPF market, enhancing MannKind's revenue base and pipeline valuation amidst a challenging biotech sector.
Evidence
Get alerted when MNKD changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.